Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osilodrostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 known ✓ | P15538 | 7/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 17/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osilodrostat SCHEMBL30395982 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL1037475 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL1037474 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL14761109 | 0.99 | CYP11B2 (0.98) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL16280483 | 0.99 | CYP11B2 (0.98) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL13837602 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL15128942 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL30395736 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1039611 | 0.93 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1040487 | 0.92 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| WO-2025068949-A1 | EMRUSOLMIN FOR USE IN TREATING MULTIPLE SYSTEM ATROPHY | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2025-04-03 | — | — | WO | claimed |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | claimed |
| EP-4370128-A1 | TREATMENT OF INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2024-05-22 | — | — | EP | claimed |
| EP-4356142-A1 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | Endothelium Scanning Nanotechnology Limited (AU) | 2024-04-24 | — | — | EP | claimed |
| EP-2836228-B1 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2024-03-20 | — | — | EP | claimed |
| EP-3560959-B1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-11-22 | — | — | EP | claimed |
| WO-2023161326-A1 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-08-31 | — | — | WO | claimed |
| CN-111592546-B | Preparation method of adestat | 上海鲲博玖瑞医药科技发展有限公司 | 2023-08-25 | — | — | CN | claimed |
| EP-2804863-A1 | NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR | Novartis AG (CH) | 2014-11-26 | — | — | EP | claimed |
| EP-2256118-B1 | Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | claimed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | claimed |
| US-20130287789-A1 | Organic Compounds | NOVARTIS AG (CH) | 2013-10-31 | — | — | US | claimed |
| WO-2013153129-A1 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-17 | — | — | WO | claimed |
| WO-2013109514-A1 | NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR | NOVARTIS AG (CH) | 2013-07-25 | — | — | WO | claimed |
| EP-1919916-B1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | claimed |
| US-20120295888-A1 | USE OF AN ADRENAL HORMONE-MODIFYING AGENT | RECORDATI AG (CH) | 2012-11-22 | — | — | US | claimed |
| US-8314097-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| CN-102711916-A | Use of adrenal hormone modulators | NOVARTIS AG | 2012-10-03 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | IFNAR1, IFNG, IRF3 | CYP11B1 210/4885CYP11B2 504/4885CYP19A1 1967/4885 |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | CYP11B1 2415/4885CYP11B2 2782/4885CYP19A1 2565/4885 |
| US-20130287789-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B1 5/4885CYP11B2 14/4885CYP19A1 1/4885 |
| US-20120295888-A1 | USE OF AN ADRENAL HORMONE-MODIFYING AGENT | MC2R, NR3C2, NR3C1 | CYP11B1 25/4885CYP11B2 29/4885CYP19A1 66/4885 |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | BDKRB2, BDKRB1, HRH2 | CYP11B1 3065/4885CYP11B2 2429/4885CYP19A1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.